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SUMMARY 
 
Protein phosphatase activity acts as a primary determinant of the extent and duration of phosphorylation 
of cellular proteins in response to physiological stimuli. Ser/Thr protein phosphatase-1 (PP1) belongs to the PPP 
superfamily, and is associated with regulatory subunits that confer substrate specificity, allosteric regulation and 
subcellular compartmentalization.  In addition, all eukaryotic cells contain multiple heat-stable proteins that 
originally were thought to inhibit phosphatase catalytic subunits released from the regulatory subunits, as a fail-
safe mechanism. However, discovery of CPI-17 required fresh thinking about the endogenous inhibitors as 
specific regulators of particular phosphatase complexes, acting in addition to, not instead of, regulatory 
subunits.  The cellular actions of the endogenous inhibitors are controlled by phosphorylation, connecting them 
to kinase pathways. More recent progress has unveiled additional functions of PP1 inhibitor-2 (I-2), including 
regulation of protein kinases.  Transcriptional mechanisms govern the expression levels of CPI-17 in response 
to stimuli. If true for other inhibitor proteins, they have the potential of being diagnostic markers for 
pathological conditions. We discuss specific examples of PP1 inhibitor proteins regulating particular cellular 
functions and the rationale for incorporating phosphatase inhibitor proteins in development of new therapeutic 
strategies. 
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I. INTRODUCTION:  
Protein phosphatases modulate stimulus-response:  Over the past 50 years protein phosphorylation 
has been firmly established as a fundamental mechanism for cell signaling, vital to every aspect of biology and 
pathophysiology. Protein phosphatases as well as kinases are positively and negatively regulated in response to 
hormonal and neuronal inputs, as well as environmental stresses (1). Figure 1A shows kinase activation in 
response to a cellular stimulus that increases protein phosphorylation.  When protein phosphatase activity is 
coincidently suppressed this stimulus-response curve is shifted to the left, and relatively less kinase activity is 
needed to produce phosphorylation (a process called sensitization, left curve in Figure 1A). An outstanding 
example is the Ca
2+
 dependent myosin light chain phosphorylation and smooth muscle contraction that are 
controlled through the negative regulation of the myosin light chain phosphatase (MLCP) (2). By contrast, 
higher phosphatase activity requires more kinase activity to achieve phosphorylation of substrates, causing de-
sensitization in the response to stimuli (right-shift of the activation curve in Figure 1A). For example, 
dexamethasone induction of dual specificity phosphatases (called DUSP or MKP) suppresses responses to 
stimuli by limiting the phosphorylation and activation of MAPKs. (3). Thus, there are examples where changes 
in phosphatase activity modify cellular responses to stimuli. Kinases have become a focus for drug discovery, 
but phosphatase regulation needs to be taken into account for a better understanding of the responses and 
resistance to these new pharmaceuticals.   
 
Diversity of Ser/Thr phosphatases:  There are at least three distinct superfamilies of Ser/Thr 
phosphatases based on structures and mechanisms (1). The major family is called PPP, with three predominant 
phosphatases PP1, PP2A and Ca
2+
/calmodulin-dependent calcineurin (CaN, a.k.a. PP3), in addition the PPP 
family has other members including PP4, PP5 and PP6. Activities of PPP in cells are restricted primarily 
through interaction with regulatory subunits that are responsible for compartmentalization, allosteric regulation 
and substrate specificity. Our favorite example is the myosin-binding PP1 regulatory subunit (MYPT1) that 
tethers the catalytic subunit of PP1 (PP1C) to actomyosin filaments for the dephosphorylation of myosin 
regulatory light chain MLC20 in smooth muscle and non-muscle cells, such as fibroblasts. Phosphorylation of 
MYPT1 at Thr696 and Thr853 causes inhibition of the myosin phosphatase (Figure 1B , scheme (i)), allowing 
for multiple kinase inputs to alter phosphatase activity. Because each PPP catalytic subunit interacts with a 
variety of regulatory subunits, including >100 regulatory subunits for PP1, and three or four families of B 
regulatory subunits for PP2A,  the number of individual Ser/Thr phosphatase combinatorial complexes 
approaches the number of Ser/Thr kinases, encoded by approximately 400 genes in human genome.  
 
Inhibitor Proteins for PPP Ser/Thr phosphatases:  In addition to regulatory subunits, PPP 
phosphatases are regulated by endogenous polypeptide inhibitors.    Table 1 lists inhibitor proteins for PP1, 
PP2A and CaN in mammals. Most PP1 inhibitor proteins are phosphorylated at multiple sites and 
phosphorylation governs their functions. For example, I-1, DARPP32, CPI-17, and its homologs PHI-1, KEPI 
and GBPI all are phosphorylation-dependent inhibitors for PP1. Likewise, -endosulfine (Ensa) and ARPP19 
were identified as selective inhibitors of PP2A due to phosphorylation at Ser67 by Greatwall kinase (4, 5). On 
the other hand, I-2, I-3, I-4, NIPP1, SET/I2
PP2A
, cain/cabin1, and RCAN1 spontaneously bind to their 
phosphatase target without phosphorylation, even though functions are modulated by phosphorylation (Table 1) 
(6-9). The phosphorylation dependence of the inhibitor proteins is partly how kinase activation transduces into 
changes in protein phosphorylation, by coincident reduction in phosphatase activity. Phosphorylation-dependent 
modulation of the inhibitor proteins is key to accurate mapping and modeling of signaling networks.  
 
The first PP1 inhibitors discovered, I-1 and I-2, proved relatively ineffective as inhibitors in biochemical 
assays with PP1C complexed with glycogen-targeting subunit (GM) or myosin-targeting subunit (MYPT1), 
compared to monomeric PP1 catalytic subunit.  In 1993, a model illustrated in Figure 1B (iii) was proposed 
where dissociation of regulatory subunit releases PP1C, making it available for inhibition by PP1 inhibitors 
(10). The model was based on PKA phosphorylation of Ser67 in the RVSF PP1 binding motif of GM, which 
released PP1C.  The model involved simultaneous phosphorylation of GM and I-1 by PKA with net transfer of 
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PP1C from the former to the latter binding partner (Figure 1B, scheme (iii)) (10). Rapid and reversible binding 
of PP1C with multiple regulatory subunits is vital to this “scavenger” model for the action of PP1 inhibitors, 
which was popular and even made its way into textbooks. However, the scavenger model has some problems. 
There was no evidence for formation of the phospho-I-1::PP1C complex in response to PKA activation. The 
model has no path for return to the initial state of the PP1 bound to GM. Later, a new inhibitor CPI-17 was 
discovered that has no RVxF motif for tethering to PP1C, but interacts with PP1C that is bound to the 
regulatory subunit MYPT1. The example of CPI-17 showed that PP1 inhibitors bind in addition to, not instead 
of, regulatory subunits. Contacts of CPI-17 with both subunits (PP1C and MYPT1) allows this protein to 
selectively inhibit one subset of PPP holoenzymes (Figure 1B, scheme (iv)) (11). This new model explains how 
specific phenotypes could be caused by the ablation, mutation, or pathological overexpression of particular 
endogenous inhibitor protein genes.  
 
 
II. Specificity of Individual PP1 inhibitors 
 
CPI-17, a selective inhibitor of PP1C::MYPT1:  CPI-17 (C-kinase-activated PP1 inhibitor, Mr of 
17kDa) was discovered by biochemical purification using an assay for phosphorylation-dependent inhibition of 
the MLCP complex (reviewed in (11)). Inhibition occurs without dissociation of PP1C and the IC50 is 
enhanced over 1,000-fold (µM to nM) when CPI-17 is phosphorylated at Thr38. Neither Asp- nor Glu-
substitution of Thr38 can mimic phosphorylation to produce the inhibitory effects.  Thr38 is phosphorylated by 
multiple kinases, such as PKC, ROCK, ILK, ZIPK, and PAK, making it a hub for inputs to increase myosin 
phosphorylation and contractility (11). Upon G-protein activation CPI-17 is phosphorylated and selectively 
inhibits the MLCP, promoting an increase in the phosphorylation of myosin and also other MLCP substrates 
such as merlin (12, 13). CPI-17 expression is restricted in specific cell types, where it contributes to the 
regulation of specific cell functions, such as smooth muscle contraction, platelet activation, Purkinje cell long-
term depression, endothelium function, cancer cell growth and gene regulation (11, 13, 14).  
 
Phospho-CPI-17 inhibition is restricted to PP1C monomer or PP1C associated with MYPT1.  When 
phospho-CPI-17 binds to PP1C complexed with other regulatory subunits (e.g. PP1C::GM), it gets 
dephosphorylated, thereby losing its inhibitory potential, making CPI-17 an inhibitor AND/OR a substrate(15).  
We propose inhibition is a function of the relative rate of Thr38 dephosphorylation.  This concept also provides 
a mechanism for relief of inhibition, and resetting to basal conditions, by dephosphorylation of the bound CPI-
17. Yet another phosphatase is not required for inactivation of the phosphoinhibitor.  
 
Figure 2A shows an in silico structural model of the complex of phospho-CPI-17 (cyan) binding to 
MYPT1 (purple)•PP1 (red) (16). The solution NMR structure of CPI-17 reveals a flexible loop region with the 
phosphorylation site, followed by a bundle of four -helices, which undergo realignment upon Thr38 
phosphorylation (16).  In this 3D model, phospho-CPI-17 docks at the PP1 active site, and simultaneously 
contacts MYPT1 at the ankyrin-repeat domain and the N-terminal helix domain (Figure 2A orange circles).  In 
fact, deletion of the MYPT1 N-terminal helix greatly diminishes binding to phospho-CPI-17. We propose that 
simultaneous contacts with different subunits of PPP holoenzymes account for the specificity of the endogenous 
PPP inhibitor proteins (Table 1) (16).  
 
The CPI-17 Family:  Following the discovery of CPI-17, related proteins PHI-1, KEPI and GBPI were 
characterized as inhibitors of PP1 holoenzymes, dependent on phosphorylation at a site corresponding to CPI-
17 Thr38 (Table 1) (11).  The primary structure of CPI-17 family members is highly conserved within the 
inhibitory domain, including the phosphorylation loop, therefore it is easy to imagine that each family member 
shares the same overall architecture. Despite this, each CPI-17 family member is projected to play unique roles 
in cell signaling.  For example, PHI-1 cannot mimic CPI-17 action in permeabilized smooth muscle, but it does 
contribute to regulation of cell motility, without affecting myosin phosphorylation.  KEPI is involved in 
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mechanisms of morphine addiction (17), and its inhibitory potency toward MLCP is lower, compared to PP1C, 
distinguishing it from CPI-17 (11).  A clear difference in the sequence of PHI-1, KEPI and GBPI compared to 
CPI-17 is the presence of a RVXF motif in the N-terminal tail domain.  Unphosphorylated KEPI and GBPI 
associate with PP1, probably using this RVXF sequence, although structural insights into the interaction have 
yet to be revealed (18). 
 
Inhibitor-1 regulates cardiac ß-agonist signaling to selected targets:  I-1 has actions in the regulation 
of protein synthesis and Ca
2+
 signaling.  I-1 is phosphorylated at Thr35 by PKA to become a potent PP1 
inhibitor (Table 1) (19).  Phospho-Thr35 directly docks at the active site of PP1 as a pseudosubstrate (20).  In 
addition, the N-terminal KIQF motif, which is conserved in another inhibitor protein called DARPP32, can 
anchor to the PP1 RVxF-binding pocket, if the pocket is not occupied by a regulatory subunit.  This may be 
why phospho-I-1 is in general less potent toward PP1 complexes, compared with monomeric PP1C.  However, 
yeast two-hybrid screening with I-1 as bait identified GADD34, which binds to the C-terminal region of I-1 
(21).  GADD34 encoded by the PPP1R15A gene is a regulatory subunit that targets PP1 to translation initiation 
factor eIF-2alpha via an RVxF motif. The results support formation of a heterotrimeric complex of phospho-I-1, 
PP1C and GADD34 (Figure 2B) (21). The specific recognition of a subset of PP1 holoenzymes by I-1 may 
explain the selective regulation of the phosphorylation of phospholamban at Ser16 and ryanodine receptor at 
Ser2814, compared to troponin I and myosin-binding C-protein in cardiac ß-adrenergic signaling (see 
review(22)).  
 
 Inhibitor-2 is a mitotic phosphoprotein with multiple targets/partners: The physiological function 
of phosphatase I-2 has been a mystery for decades. Different groups purified a I-2::PP1C heterodimer that was 
studied intensively for many years, with the presumption that it represented a major form of cytosolic PP1 in 
cells and tissues. The inactive heterodimer was named MgATP-dependent phosphatase, because the 
phosphatase activity could be evoked by the phosphorylation of I-2 at Thr72 in the PSTP sequence by an 
activating factor FA, a reaction shown later to be catalyzed by Pro-directed kinases GSK3, MAPKs or CDKs 
(see (23)). Deletion and mutation analysis showed I-2 interacts with PP1C through multiple sites. The 3D 
structure of the crystallized heterodimer visualized only parts of I-2, one long helical segment across the active 
site, and other short segments in contact with PP1 (24). Other portions of I-2 apparently were too flexible to 
give an electron density map. Recent studies of I-2 binding to PP1C by NMR showed I-2 associated with PP1C 
already complexed with neurabin, forming a heterotrimer of I-2::PP1C::Nrb (25).  Based on analysis of NMR 
spectra different regions of I-2 were used to contact PP1C in the heterodimer, compared to the heterotrimer. 
These results reinforced a previous proposal that I-2 function involves heterotrimers containing PP1C and other 
partners.  Those other partners were found by yeast two-hybrid screening, and validated individually, including 
NIMA-related kinase 2 (Nek2), the kinase LMTK2, and neurabin 2 (a.k.a. spinophilin) (1). These proteins each 
form a trimeric complex with I-2 and PP1C. Other studies found I-2 directly binds and activates Aurora A 
kinase (26) and forms heterotetramers with the prolyl isomerase Pin1 (27), which alters Pin1 specificity for 
mitotic phosphoproteins (28). These complexes do not involve PP1C at all. Taken together, results indicate that 
I-2 forms heterotrimers with PP1C and also has other potential targets in cells, not just PP1C.  
 
Genetics and cell biology point to a conserved biological function of I-2 in control of chromosome 
segregation during mitosis, probably involving Aurora B.   First, in yeast the I-2 ortholog GLC8 regulates PP1 
(GLC7) and Aurora (IPL1) for proper chromosome segregation (29). Second, a phospho-specific antibody 
exposed a >25-fold increase in phosphorylation of the conserved PxTP motif in HeLa cells blocked in mitosis 
(30). Third, in growth synchronized cells going from G2 through mitosis the rise and fall of phospho-I-2 exactly 
paralleled the phosphorylation of histone H3 Ser10 and the inhibitory phospho-Thr in PP1, consistent with these 
being common substrates of CDK1::cyclinB1 (31). Fourth, knockdown of I-2 in human epithelial cells caused a 
failure of cytokinesis and accumulation of cells with multipolar mitotic spindles and defective nuclei (32). 
Knockdown and overexpression of I-2 shifted the dose-response for Aurora B inhibitors. Lastly, in vivo and 
genetic evidence from Drosophila revealed maternal expression and essential function (33). Using a species-
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specific antibody, Dm-I-2 was visualized by immunofluorescent microscopy as a maternal protein loaded into 
oocytes during maturation. Phospho-I-2 was localized in vivo in bands of mitotic cells during gastrulation. 
Genetic crosses produced hypomorphic embryos that showed loss of mitotic synchrony, defective mitotic 
spindles with lagging chromosomes, and loss of nuclei in syncytial blastoderms, resulting in reduced viability. 
Transgenic expression of Dm-I-2 gave dose-dependent rescue of the maternal effect lethality (33). Thus, I-2 is a 
mitotic phosphoprotein that has an essential role in chromosome segregation.  
 
 
III. Longer-term Changes in Expression Levels of Inhibitor Proteins. 
 
Transcriptional regulation of CPI-17: Responses of cells to physiological stimuli and pathological 
stresses involve both early responses by post-translational modification of the PPP inhibitor proteins (Figure 
1B) plus later transcriptional regulation of the genes. For example, CPI-17 is involved in the early and late 
responses in smooth muscle contraction (Figure 3). GPCR activation triggers quick activation of conventional 
PKC through Ca
2+
 release from SR in smooth muscle cells. ROCK is activated through Rho-GEF signaling, 
causing sustained phosphorylation of CPI-17 and parallel inhibition of MLCP by MYPT1 phosphorylation (11). 
CPI-17 expression levels are altered during embryonic development and perturbed under pathological 
conditions, as listed in Table 2.  CPI-17 expression increases during the course of development of smooth 
muscle cells in the embryo (34). Elevation of CPI-17 expression is linked to hyper-responsiveness of smooth 
muscle contraction, such as in the pregnant myometrium, diabetes mellitus and bronchus of asthma models and 
patients (35-38).  Hypoxia, androgen treatment, subarachnoid hemorrhage and mechanical obstruction also lead 
to CPI-17 upregulation (39-42).    On the other hand, CPI-17 expression can be down-regulated.  In intestinal 
smooth muscle, inflammatory cytokine stimulation causes reduction of CPI-17 expression and loss of smooth 
muscle tone (43).  Furthermore, even in the same organ (urinary bladder) the response of CPI-17 expression is 
different for mouse vs. rabbit (44) (Table 2). Thus, the regulatory network for controlling CPI-17 expression 
seems to be a specific adaptation to environmental changes in different smooth muscles. The regulation of CPI-
17 expression is mediated in part though kinase signaling (Figure 3) (45).  A potent smooth muscle growth 
factor, platelet derived growth factor (PDGF) ceases the CPI-17 gene promoter, which is regulated by Sp1/Sp3 
binding (45).  This is consistent to the downregulation of CPI-17 expression at vascular lesions (34).  
Interestingly, the CPI-17 promoter is independent of KLF4/myocardin signaling, which is a dominant regulator 
of smooth muscle genes.  Osmotic stress and inflammatory cytokine signals can cause upregulation of the CPI-
17 gene through p38/JNK pathways, which likely dominate in bronchial smooth muscle, where inflammation 
upregulates CPI-17 expression. On the other hand, ERK1/2 signals or other inhibitory pathways are likely 
involved in downregulation of CPI-17 in inflamed intestine.   PKC and ROCK positively regulate the CPI-17 
promoter, indicating dual roles of these kinases in the early and late response in the CPI-17 signaling (45).  
These results suggest coupling of CPI-17 activation and expression to enhance smooth muscle responsiveness to 
stimuli. A growing body of evidence also suggests that fluctuations occur in the expression of a subset of the 
PPP inhibitor proteins, such as RCAN1, SET/I2
PP2A
, DARPP32 and CIP2A, under pathological conditions. 
Thus, changes in gene expression of endogenous inhibitor proteins are part of adaptation in the disease state. 
Therefore the PPP inhibitor proteins have potential as diagnostic markers and possibly as therapeutic targets.  
 
Alternative splicing of PP1 inhibitor proteins:  Splicing variants and isoforms of PP1 inhibitor 
proteins with disparate activities are expressed under different pathophysiological conditions. A truncated 
version of CPI-17 called ß includes Thr38, but lacks 27 residues in the middle region encoded by exon 2, which 
includes the hydrophobic residues necessary for the four-helix bundle. This would be predicted to lack 
structural stability and inhibitory potency (16, 46).  A shorter isoform of I-2 called ß is encoded by an 
independent gene expressed in testis.  This I-2ß gene product lacks both N-terminal and C-terminal regions of 
the conventional I-2 and fails to inhibit PP1C (47).  I-1 splicing variants, I-1 and I-1ß, are generated due to 
loss of exon 4 and exon 5 that might alter target recognition, even though these shorter versions have the 
inhibitory phosphorylation site Thr35 and retain the inhibitory potency with PP1C (48, 49).  One study using 
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yeast suggests that the physiological functions of the truncated I-1/ß are distinguishable from the conventional 
I-1 (49). Alternative splicing that deletes functional regions can change the target oPP1 inhibitors and alter the 
cellular response.  It is possible that some variants that do not inhibit PP1C still possess phosphorylation sites 
and may function as decoys or competitors in cells.  Physiological significance of these PP1 inhibitor variants is 
underestimated.  
 
 
IV. Prospects for future study of endogenous PPP inhibitor proteins:  
 
 Our view is that the primary action of each endogenous inhibitor protein is to provide regulation of 
individual PPP phosphatase holoenzymes by simultaneous interaction with the catalytic and regulatory subunits. 
In this way the phospho-regulation of a subset of the PPP inhibitors provides a way for kinases to fine-tune the 
activity of particular phosphatase holoenzymes in response to signaling stimuli. Natural products such as 
okadaic acid, calyculin A, and microcystin-LR, inhibit multiple PPP phosphatases by binding at the active sites, 
and pose limited translational potential, due to toxicity. In contrast, as discussed, many endogenous inhibitor 
proteins potentially regulate a narrow subset of PPP enzymes, at particular times and locations, contributing to 
temporal and spatial control of cell signaling.  Cellular PPP inhibitor proteins can be regulated by 
transcriptional and post-translational mechanisms. We confidently can predict there are more gene products to 
be discovered as PPP phosphatase inhibitors. Because the levels of the endogenous inhibitor change in different 
pathophysiological situations, they may serve as diagnostic markers. These PPP inhibitors may even be 
therapeutic targets. Interfering with the PP2A inhibitor called SET/I2
PP2A
 to increase PP2A phosphatase activity 
is already being exploited as a possible therapeutic approach (50, 51).  Guanabenz is a compound recently 
characterized as a specific inhibitor of the GADD34-PP1 complex, which gives resistance to ER-stress by 
maintaining eIF2alpha phosphorylation, in effect mimicking one action of I-1 (52). Structural insights into how 
the endogenous inhibitors generate specificity by recognition of PPP could be applied to the design of new 
antagonists that recognize individual PPP holoenzymes to elicit specific physiological responses.  
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Table 1: Mammalian endogenous inhibitor proteins for PPP superfamily 
 
Inhibitor Phosphorylation site Kinase Function Reference 
PP1 inhibitors 
  Inhibitor-1 (I-1) Thr35 PKA Inhibition of PP1 (53) 
 Ser67 Cdk5/PKC Inhibition of PKA (54) 
 
  DARPP32 Thr34 PKA Inhibition of PP1 reviewed in (55) 
 Thr75 Cdk5 Inhibition of PKA (55) 
 Ser97 CK-II Exposing Thr34 (55) 
 Ser130 CK-I Inhibition of CaN (55) 
 
  Inhibitor-2 (I-2) Thr72 GSK3, cdc2, MAPK Activation of PP1C•I-2 complex (6) 
 Ser86/120/121 CK-II Recognition of Thr72 by GSK3 (6) 
 Tyr  ND
a
 (56) 
  Inhibitor-4 (I-4)   I-2 homolog  
 
  Inhibitor-3 (I-3) ND PKA, PKC, CK-II Dis-inhibition  (7) 
   
  NIPP-1 Ser199 PKA Activation of PP1C•NIPP-1 complex (8) 
 Ser204 CK-II Activation of PP1C•NIPP-1 complex (57) 
   
  CPI-17 Thr38 PKC, ROCK, ZIPK, ILK Inhibition of PP1∂-MYPT1 complex reviewed in (11) 
 Ser12 PKC, ZIPK ND  (11)
 
 Ser128 ND ND  (11) 
 
  PHI-1 Thr57 PKC, ROCK, ILK Inhibition of PP1 (58) 
 Ser
b
 PKC, ROCK ND (58) 
 
  KEPI Thr73 PKC, ILK Inhibition of PP1  (59) 
 Ser
b
 PKC ND (60) 
 
  GBPI Thr58 PKC Inhibition of PP1 (18) 
 Ser
b
 PKA Dis-inhibition (18) 
 
PP2A inhibitor 
  SET/I2
PP2A
   Upregulated in cancer cells  

  CIP2A   Upregulated in cancer cells  

-endosulfine (Ensa) Ser67 Greatwall Inhibition of PP2A-B55∂ complex (5) 
  ARPP19 Ser67 Greatwall Inhibition of PP2A-B55∂ complex (4) 
 
CaN/PP2B inhibitors 
  CAIN/CABIN   Inhibition of CaN  
 
  RCAN1 Ser163 ND Inhibition of CaN (9) 
  
 
a
 ND, not determined. 
b
 Phosphorylation site(s) are not identified. 
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Table 2:  Fluctuations in CPI-17 expression under physiological and pathological conditions 
 
_______________________________________________________________ 
 
  Tissue Treatment/Condition Reference 
_______________________________________________________________ 
 
 
UPREGULATION 
 
  Human myometrium  Pregnancy (35) 
  Pig pulmonary artery  Hypoxia (39) 
  Rat bronchus  Antigen challenge (37) 
  Human bronchus Asthma (38) 
  Rabbit bladder  Hyperglycemia (36) 
  Mouse bladder  Partial urinary outlet obstruction  (42) 
  Rabbit cerebral artery  Subarachonoid hemorrhage (41) 
  Rat renal cortex Testosterone treatment (40) 
  Cancer cells  (13) 
 
 
DOWNREGULATION 
   
  Rat artery Neointima (34) 
  Mouse ileum IL1ß, inflammatory bowel disease (43) 
  Human colon Chronic colitis (43) 
  Rabbit bladder Partial urinary outlet obstruction (44) 
_______________________________________________________________ 
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Figure Legend 
 
Figure 1: Regulation of Ser/Thr phosphatases. A. Phosphatase Regulation of cellular responses.  
Phosphorylation is increased by the strength of stimulation that activates a kinase.  Inhibition and activation of 
the opposing phosphatase causes left and right shifts of the stimulation-phosphorylation curve (sensitization and 
de-sensitization), respectively. B.  Schemes in phosphatase regulation.  I: PPP inhibitor protein.  Scheme: i) 
phosphorylation of regulatory subunit causes allosteric inhibition of the holoenzyme, dissociation/scavenger 
model, ii) regulatory factor, such as CaM for CaN, relieves inhibition holoenzyme, iii) phosphorylation or 
degradation of regulatory subunit releases catalytic subunit, which is inhibited by an endogenous inhibitor 
protein, iv) An inhibitor protein directly binds to holoenzyme without subunit dissociation, and v) An PPP 
inhibitor protein regulates other, non-phosphatase proteins. 
 
Figure 2:  Models of PP1 holoenzymes with PP1 inhibitors.  A. MYPT1•PP1•CPI-17, B. GADD34•PP1•I-1. 
In the new PP1 heterotrimer model, PP1 inhibitor protein (cyan) directly binds to a complex of PP1 catalytic 
subunit (red) and regulatory subunit (purple).  The direct contact between PP1 inhibitor protein and regulatory 
subunit may contribute to the specific recognition of PP1 holoenzymes.   
 
 
Figure 3: Multi-phase regulation of MLCP through CPI-17.  GPCR activation triggers activation of PKC 
and ROCK, which leads to a sequential phosphorylation of CPI-17 and a quick and robust phosphorylation of 
myosin light chain in smooth muscle.  In addition to the early response, PKC/ROCK, as well as p38/JNK 
activated under pathological stresses upregulates the CPI-17 promoter, and the growth stimulation with PDGF 
negatively regulates the expression through ERK1/2, adjusting MLCP signaling to environmental changes.   
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